tazobactam has been researched along with Acinetobacter Infections in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Cattoir, V; Corvec, S; Drugeon, H; Faccone, D; Galas, M; Mugnier, P; Nordmann, P; Pasteran, F; Petroni, A; Poirel, L; Rapoport, M | 1 |
| Chan, MC; Chang, TY; Chiueh, TS; Sun, JR; Wang, WY | 1 |
| Ju, YG; Lee, HJ; Lee, MG; Sohn, JW; Yim, HS; Yoon, YK | 1 |
| Akyüz, S; Güdücüoğlu, H; Parlak, M | 1 |
| Alaghehbandan, R; Alinejad, F; Azimi, L; Lari, AR; Tahbaz, SV | 1 |
| Kharat, AS; Khobragade, K; Palwe, S; Periasamy, H; Veeraraghavan, B | 1 |
| Monogue, ML; Nicolau, DP; Nizet, V; Sakoulas, G | 1 |
| Alyousef, AA; Alzahrani, AJ; Krishnappa, LG; Marie, MA; Mubaraki, MA | 1 |
| Berti, A; Munguia, J; Nizet, V; Nonejuie, P; Olson, J; Pogliano, J; Rose, W; Rybak, MJ; Sakoulas, E; Sakoulas, G | 1 |
| Choi, MK; Fish, DN; Husain, M; Jung, R | 1 |
| Higgins, PG; Seifert, H; Stefanik, D; Wisplinghoff, H | 1 |
| Clapson, P; Debien, B; Leclerc, T; Lenoir, B; Perez, JP | 1 |
| Cuenca, FF | 1 |
| Nishino, T; Obana, Y | 1 |
1 review(s) available for tazobactam and Acinetobacter Infections
| Article | Year |
|---|---|
[Activity of betalactamase inhibitors against Acinetobacter baumannii].
Topics: Acinetobacter; Acinetobacter Infections; Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Humans; Penicillanic Acid; Sulbactam; Tazobactam | 2000 |
13 other study(ies) available for tazobactam and Acinetobacter Infections
| Article | Year |
|---|---|
Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina.
Topics: Acinetobacter; Acinetobacter Infections; Amino Acid Sequence; Anti-Bacterial Agents; Argentina; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Clavulanic Acid; Cloning, Molecular; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Sequence Analysis, DNA | 2007 |
Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aged; Aged, 80 and over; Bacterial Proteins; Carbapenems; Drug Resistance, Bacterial; Female; Humans; Male; Membrane Transport Proteins; Middle Aged; Minocycline; Molecular Sequence Data; Mutagenesis, Insertional; Reverse Transcriptase Polymerase Chain Reaction; Tigecycline | 2010 |
In vitro synergistic antimicrobial activity of a combination of meropenem, colistin, tigecycline, rifampin, and ceftolozane/tazobactam against carbapenem-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Colistin; Drug Combinations; Drug Synergism; Humans; Meropenem; Microbial Sensitivity Tests; Rifampin; Tazobactam; Tigecycline | 2022 |
[In-vitro Activity of Ceftolozane-Tazobactam in Combination with Various Antibiotics Against Multidrug-resistant Acinetobacter baumannii Isolated from Intensive Care Patients].
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Tazobactam | 2020 |
Synergistic Effect of Tazobactam on Amikacin MIC in Acinetobacter baumannii Isolated from Burn Patients in Tehran, Iran.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; Burns; Drug Resistance, Multiple, Bacterial; Drug Synergism; Genes, Bacterial; Humans; Iran; Microbial Sensitivity Tests; Tazobactam | 2020 |
Unorthodox Parenteral β-Lactam and β-Lactamase Inhibitor Combinations: Flouting Antimicrobial Stewardship and Compromising Patient Care.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Antimicrobial Stewardship; beta-Lactamase Inhibitors; Cephalosporins; China; Drug Combinations; Drug Misuse; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Inappropriate Prescribing; India; Microbial Sensitivity Tests; Patient Care; Pseudomonas aeruginosa; Pseudomonas Infections; Sulbactam; Tazobactam | 2020 |
Humanized Exposures of a β-Lactam-β-Lactamase Inhibitor, Tazobactam, versus Non-β-Lactam-β-Lactamase Inhibitor, Avibactam, with or without Colistin, against Acinetobacter baumannii in Murine Thigh and Lung Infection Models.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Azabicyclo Compounds; Colistin; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Synergism; Female; Humans; Lung; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam; Thigh | 2018 |
A prospective evaluation of synergistic effect of sulbactam and tazobactam combination with meropenem or colistin against multidrug resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Colistin; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Prospective Studies; Sulbactam; Tazobactam; Thienamycins | 2015 |
Classical β-Lactamase Inhibitors Potentiate the Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus and Colistin against Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; beta-Lactamase Inhibitors; Cathelicidins; Cell Membrane; Colistin; Daptomycin; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Humans; Methicillin-Resistant Staphylococcus aureus; Mice, Inbred BALB C; Microbial Sensitivity Tests; Penicillanic Acid; Pneumonia, Bacterial; Tazobactam | 2017 |
Synergistic activities of moxifloxacin combined with piperacillin-tazobactam or cefepime against Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii clinical isolates.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Infective Agents; Aza Compounds; Cefepime; Cephalosporins; Colony Count, Microbial; Drug Synergism; Enterobacter cloacae; Enterobacteriaceae Infections; Enzyme Inhibitors; Fluoroquinolones; Humans; Klebsiella Infections; Klebsiella pneumoniae; Moxifloxacin; Penicillanic Acid; Penicillins; Piperacillin; Quinolines; Tazobactam | 2004 |
In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Clavulanic Acid; DNA; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Electrophoresis, Gel, Pulsed-Field; Enzyme Inhibitors; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam | 2004 |
[Treatment of a septic shock due to multiresistant Acinetobacter baumannii with tigecycline in combination].
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Minocycline; Penicillanic Acid; Piperacillin; Shock, Septic; Tazobactam; Tigecycline; Trimethoprim, Sulfamethoxazole Drug Combination | 2007 |
In-vitro and in-vivo activities of sulbactam and YTR830H against Acinetobacter calcoaceticus.
Topics: Acinetobacter; Acinetobacter Infections; Animals; beta-Lactamase Inhibitors; Humans; Male; Mice; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam | 1990 |